Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03729518 · ClinicalTrials.gov registry record · NA
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
A NA study of Squamous Cell Carcinoma and Human Papilloma Virus, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT03729518: Active NA study of Squamous Cell Carcinoma and Human Papilloma Virus, sponsored by Abramson Cancer Center at Penn Medicine.
NCT03729518 is a NA study of Squamous Cell Carcinoma and Human Papilloma Virus that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 150 participants, above the 101-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (49% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03729518, a NA study of Squamous Cell Carcinoma and Human Papilloma Virus, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-arm Phase II study of adjuvant radiation for locally advanced p16+ oropharyngeal squamous cell carcinoma. The main purpose of this research is to determine the likelihood of cancer growing back in the throat or in the neck two years after completion of radiation if lower doses of radiation are used to a smaller area of the head and neck region than is currently used in standard of care.
Primary Outcome
Number of patients with 2-year locoregional control, defined as control at the primary site and in the neck, in patients undergoing de-intensified radiation to the primary site and regional lymphatics after Transoral Robotic Surgery (TORS) and neck dissection for p16+ oropharyngeal squamous cell carcinoma (OPSCC)
Conditions Studied
Interventions
- RADIATION Radiation Therapy (IMRT or IMPT)
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2018-10-11 |
| Est. Completion | 2026-05 |
| Phase | NA |
What the registry record for NCT03729518 still lists
NCT03729518 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 101-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (49% higher).
The record links to 3 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy (IMRT or IMPT) is the first listed.
NCT03729518 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03729518 about?
NCT03729518 is a clinical study titled "TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck". This is a single-arm Phase II study of adjuvant radiation for locally advanced p16+ oropharyngeal squamous cell carcinoma. The main purpose of this research is to determine the likelihood of cancer growing back in the throat or in the neck two years after completion of radiation if lower doses of ra...
What is the current status of trial NCT03729518?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2018-10-11. Estimated completion is 2026-05.
What conditions does trial NCT03729518 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Human Papilloma Virus, Oropharyngeal Cancer.
What interventions are being tested in trial NCT03729518?
The interventions under investigation include: Radiation Therapy (IMRT or IMPT) (RADIATION).
Who is sponsoring clinical trial NCT03729518?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03729518 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03729518's enrollment target sits among peer trials
150 9th of 47 higher than 38 of 47 other Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
RECRUITING · NA
-
Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain
RECRUITING · NA
-
Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease
ACTIVE NOT RECRUITING · NA
-
Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery
COMPLETED · NA
-
Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx
COMPLETED · NA
-
Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI